Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and BeyondSpring (NASDAQ:BYSI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Risk & Volatility
Oramed Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.
Profitability
This table compares Oramed Pharmaceuticals and BeyondSpring’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -5.17% | -4.54% |
| BeyondSpring | N/A | N/A | -28.88% |
Institutional & Insider Ownership
12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Oramed Pharmaceuticals and BeyondSpring, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| BeyondSpring | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Oramed Pharmaceuticals and BeyondSpring”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $2.00 million | 83.20 | $64.05 million | $4.12 | 0.97 |
| BeyondSpring | $1.75 million | 14.50 | -$1.01 million | ($0.12) | -5.14 |
Oramed Pharmaceuticals has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Oramed Pharmaceuticals beats BeyondSpring on 9 of the 12 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
About BeyondSpring
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
